Exenatide for Stress Hyperglycemia

NCT01969149 on ClinicalTrials.gov · last registry update 2017-10-06

Finished December 2015, after enrolling 110 people. Primary outcome, as filed: Percentage of patients spending more than 50 % of the time in the glycemic target range (100 to 140 mg/dl).

Status: COMPLETED
Phase: P2/P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor type: Other
Enrollment: 110
Started: 2015-01
Primary completion: 2015-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of patients spending more than 50 % of the time in the glycemic target range (100 to 140 mg/dl)

Conditions studied

Stress Hyperglycemia

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.